An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

NCT07669610 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Cancer (TNBC)

Interventions

DRUG: SHR- A1811
DRUG: SHR-A1811+BEV

Sponsor

Fudan University